177 related articles for article (PubMed ID: 37197667)
21. Novel Effector Phenotype of Tim-3
Liu Z; McMichael EL; Shayan G; Li J; Chen K; Srivastava R; Kane LP; Lu B; Ferris RL
Clin Cancer Res; 2018 Sep; 24(18):4529-4538. PubMed ID: 29712685
[No Abstract] [Full Text] [Related]
22. CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab).
Fietz S; Zarbl R; Niebel D; Posch C; Brossart P; Gielen GH; Strieth S; Pietsch T; Kristiansen G; Bootz F; Landsberg J; Dietrich D
Cancer Immunol Immunother; 2021 Jun; 70(6):1781-1788. PubMed ID: 33196890
[TBL] [Abstract][Full Text] [Related]
23. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
[TBL] [Abstract][Full Text] [Related]
24. Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4.
Mo X; Zhang H; Preston S; Martin K; Zhou B; Vadalia N; Gamero AM; Soboloff J; Tempera I; Zaidi MR
Cancer Res; 2018 Jan; 78(2):436-450. PubMed ID: 29150430
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
26. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of PLGA containing anti-CTLA4 inhibited endometriosis progression by regulating CD4+CD25+Treg cells in peritoneal fluid of mouse endometriosis model.
Liu Q; Ma P; Liu L; Ma G; Ma J; Liu X; Liu Y; Lin W; Zhu Y
Eur J Pharm Sci; 2017 Jan; 96():542-550. PubMed ID: 27989857
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.
Liu W; Liu Y; Hu C; Xu C; Chen J; Chen Y; Cai J; Yan G; Zhu W
Int J Cancer; 2021 Sep; 149(6):1369-1384. PubMed ID: 34086978
[TBL] [Abstract][Full Text] [Related]
29. Regulatory T cells expressing abundant CTLA-4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer.
Matoba T; Imai M; Ohkura N; Kawakita D; Ijichi K; Toyama T; Morita A; Murakami S; Sakaguchi S; Yamazaki S
Int J Cancer; 2019 Jun; 144(11):2811-2822. PubMed ID: 30485427
[TBL] [Abstract][Full Text] [Related]
30. Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGFbeta gene variants.
Barreto M; Ferreira RC; Lourenço L; Moraes-Fontes MF; Santos E; Alves M; Carvalho C; Martins B; Andreia R; Viana JF; Vasconcelos C; Mota-Vieira L; Ferreira C; Demengeot J; Vicente AM
BMC Immunol; 2009 Jan; 10():5. PubMed ID: 19173720
[TBL] [Abstract][Full Text] [Related]
31. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells.
Dilek N; Poirier N; Hulin P; Coulon F; Mary C; Ville S; Vie H; Clémenceau B; Blancho G; Vanhove B
PLoS One; 2013; 8(12):e83139. PubMed ID: 24376655
[TBL] [Abstract][Full Text] [Related]
32. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.
Kavanagh B; O'Brien S; Lee D; Hou Y; Weinberg V; Rini B; Allison JP; Small EJ; Fong L
Blood; 2008 Aug; 112(4):1175-83. PubMed ID: 18523152
[TBL] [Abstract][Full Text] [Related]
33. Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity.
Watanabe T; Ishino T; Ueda Y; Nagasaki J; Sadahira T; Dansako H; Araki M; Togashi Y
Cancer Sci; 2023 May; 114(5):1859-1870. PubMed ID: 36762794
[TBL] [Abstract][Full Text] [Related]
34. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.
Herrmann A; Priceman SJ; Swiderski P; Kujawski M; Xin H; Cherryholmes GA; Zhang W; Zhang C; Lahtz C; Kowolik C; Forman SJ; Kortylewski M; Yu H
J Clin Invest; 2014 Jul; 124(7):2977-87. PubMed ID: 24892807
[TBL] [Abstract][Full Text] [Related]
35. Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop.
Marangoni F; Zhakyp A; Corsini M; Geels SN; Carrizosa E; Thelen M; Mani V; Prüßmann JN; Warner RD; Ozga AJ; Di Pilato M; Othy S; Mempel TR
Cell; 2021 Jul; 184(15):3998-4015.e19. PubMed ID: 34157302
[TBL] [Abstract][Full Text] [Related]
36. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
Forget MA; Haymaker C; Hess KR; Meng YJ; Creasy C; Karpinets T; Fulbright OJ; Roszik J; Woodman SE; Kim YU; Sakellariou-Thompson D; Bhatta A; Wahl A; Flores E; Thorsen ST; Tavera RJ; Ramachandran R; Gonzalez AM; Toth CL; Wardell S; Mansaray R; Patel V; Carpio DJ; Vaughn C; Farinas CM; Velasquez PG; Hwu WJ; Patel SP; Davies MA; Diab A; Glitza IC; Tawbi H; Wong MK; Cain S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Wargo JA; Radvanyi LG; Torres-Cabala CA; Beroukhim R; Hwu P; Amaria RN; Bernatchez C
Clin Cancer Res; 2018 Sep; 24(18):4416-4428. PubMed ID: 29848573
[No Abstract] [Full Text] [Related]
37. Low expressions of PD-L1 and CTLA-4 by induced CD4
Zhao L; Zhou X; Zhou X; Wang H; Gu L; Ke Y; Zhang M; Ji X; Yang X
Cytokine; 2020 Sep; 133():155119. PubMed ID: 32535334
[TBL] [Abstract][Full Text] [Related]
38. FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells.
Braga WM; da Silva BR; de Carvalho AC; Maekawa YH; Bortoluzzo AB; Rizzatti EG; Atanackovic D; Colleoni GW
Cancer Immunol Immunother; 2014 Nov; 63(11):1189-97. PubMed ID: 25099367
[TBL] [Abstract][Full Text] [Related]
39. The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function.
Gerold KD; Zheng P; Rainbow DB; Zernecke A; Wicker LS; Kissler S
Diabetes; 2011 Jul; 60(7):1955-63. PubMed ID: 21602513
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA profile of circulating CD4-positive regulatory T cells in human adults and impact of differentially expressed microRNAs on expression of two genes essential to their function.
Fayyad-Kazan H; Rouas R; Fayyad-Kazan M; Badran R; El Zein N; Lewalle P; Najar M; Hamade E; Jebbawi F; Merimi M; Romero P; Burny A; Badran B; Martiat P
J Biol Chem; 2012 Mar; 287(13):9910-9922. PubMed ID: 22294691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
